Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

NCT07654829 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

DRUG: KVD900 600 mg

Sponsor

KalVista Pharmaceuticals, Ltd.